QCM
CTKB icon

Quantinno Capital Management’s Cytek Biosciences CTKB Stock Holding History

Quantinno Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$252K Buy
56,823
+5,611
+11% +$24K ﹤0.01% 3257
2026
Q1 		$224K Buy
51,212
+21,564
+73% +$102K ﹤0.01% 3169
2025
Q4 		$150K Buy
+29,648
New +$138K ﹤0.01% 3097
2025
Q2 		– Sell
-21,190
Closed -$85K – 2584
2025
Q1 		$85K Buy
21,190
+6,970
+49% +$36.1K ﹤0.01% 2055
2024
Q4 		$92.3K Buy
+14,220
New +$84.7K ﹤0.01% 1622

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Quantinno Capital Management's CTKB Position: Q2 2026 in Review

Quantinno Capital Management increased its Cytek Biosciences (CTKB) stake by 11% in Q2 2026, buying an estimated $24K and bringing the position to 56,823 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #3257.

Quantinno Capital Management first reported a position in CTKB in Q4 2024 and has held it in 5 quarters since. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Quantinno Capital Management held 56,823 shares of Cytek Biosciences worth $252K as of Q2 2026.
  • Quantinno Capital Management bought 5,611 Cytek Biosciences shares in Q2 2026, an estimated $24K.
  • Cytek Biosciences made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #3257 holding.
  • Quantinno Capital Management first reported a position in Cytek Biosciences in Q4 2024 and has held it in 5 quarters since.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.